Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bicycle Therapeutics Limited

8.60
-0.0700-0.81%
Post-market: 9.030.4300+5.00%16:20 EDT
Volume:318.44K
Turnover:2.72M
Market Cap:595.14M
PE:-2.96
High:8.92
Open:8.63
Low:8.26
Close:8.67
Loading ...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Zoetis (ZTS), Walgreens Boots Alliance (WBA) and Bicycle Therapeutics (BCYC)

TIPRANKS
·
18 Dec 2024

European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading

MT Newswires Live
·
17 Dec 2024

B. Riley Adjusts Price Target on Bicycle Therapeutics to $17 From $28, Keeps Neutral Rating

MT Newswires Live
·
16 Dec 2024

Bicycle Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
16 Dec 2024

Bicycle Therapeutics Plc : H.c. Wainwright Cuts Target Price to $33 From $55

THOMSON REUTERS
·
16 Dec 2024

Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Bicycle Therapeutics (BCYC) and Quest Diagnostics (DGX)

TIPRANKS
·
16 Dec 2024

Bicycle Therapeutics Plc : H.c. Wainwright Cuts Target Price to $33 From $55

THOMSON REUTERS
·
16 Dec 2024

Sector Update: Health Care Stocks Edge Higher Late Afternoon

MT Newswires Live
·
14 Dec 2024

Bicycle Therapeutics Reports Updates Across Zelenectide Pevedotin Program; Shares Slump

MT Newswires Live
·
14 Dec 2024

Bicycle Therapeutics' Latest Trial Results Raise Questions -- Market Talk

Dow Jones
·
14 Dec 2024

Bicycle Therapeutics Is Maintained at Neutral by B. Riley Securities

Dow Jones
·
14 Dec 2024

European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading, Down 1.5% for Week

MT Newswires Live
·
14 Dec 2024

Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients

Benzinga
·
13 Dec 2024

Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging Nectin4 Gene Amplification

THOMSON REUTERS
·
13 Dec 2024

Bicycle Therapeutics Plc: Dose Selection and Topline Data From Phase 2/3 Duravelo-2 Trial Planned for 2H 2025

THOMSON REUTERS
·
13 Dec 2024

Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification

Business Wire
·
13 Dec 2024

European Equities Traded in the US as American Depositary Lower in Tuesday Trading

MT Newswires Live
·
11 Dec 2024

Bicycle Therapeutics Expands Clinical Advisory Board with Three Distinguished Global Oncology Experts

Business Wire
·
10 Dec 2024

European Equities Traded in the US as American Depositary Tread Water in Friday Trading

MT Newswires Live
·
07 Dec 2024

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire
·
03 Dec 2024